Search results
Showing 1 to 15 of 80 results for dvt
Venous thromboembolic diseases: diagnosis, management and thrombophilia testing (NG158)
This guideline covers diagnosing and managing venous thromboembolic diseases in adults. It aims to support rapid diagnosis and effective treatment for people who develop deep vein thrombosis (DVT) or pulmonary embolism (PE). It also covers testing for conditions that can make a DVT or PE more likely, such as thrombophilia (a blood clotting disorder) and cancer. It does not cover pregnant women.
Evidence-based recommendations on rivaroxaban (Xarelto) for treating deep vein thrombosis (DVT) and preventing a pulmonary embolism (PE) or another deep vein thrombosis in adults.
This guideline covers assessing and reducing the risk of venous thromboembolism (VTE or blood clots, including deep vein thrombosis and pulmonary embolism) in people aged 16 and over in hospital. It aims to help healthcare professionals identify people most at risk and describes interventions that can be used to reduce the risk of VTE.
Evidence-based recommendations on dabigatran etexilate (Pradaxa) for treating and preventing deep vein thrombosis and pulmonary embolism in adults.
Evidence-based recommendations on apixaban (Eliquis) for treating and preventing recurrent deep vein thrombosis or pulmonary embolism in adults.
Ultrasound‑enhanced, catheter‑directed thrombolysis for deep vein thrombosis (HTG375)
Evidence-based recommendations on ultrasound enhanced catheter-directed thrombolysis for deep vein thrombosis. This involves using ultrasound waves and a drug to break up the clot.
This quality standard covers reducing the risk of venous thromboembolism (VTE) in people aged 16 and over who are in hospital. It also covers diagnosing and treating VTE in all people aged 18 and over. It describes high-quality care in priority areas for improvement.
View quality statements for QS201Show all sections
Sections for QS201
- Quality statements
- Quality statement 1: Timing of pharmacological venous thromboembolism prophylaxis
- Quality statement 2: Venous thromboembolism risk assessment for people with lower limb immobilisation
- Quality statement 3: Proximal leg vein ultrasound scan for a 'likely' deep vein thrombosis Wells score
- Quality statement 4: Venous thromboembolism anticoagulation review
- Quality statement 5: Follow-up for outpatients with low-risk pulmonary embolism
- Update information
- About this quality standard
Percutaneous mechanical thrombectomy for acute deep vein thrombosis of the leg (HTG516)
Evidence-based recommendations on percutaneous mechanical thrombectomy for acute deep vein thrombosis of the leg in adults. This involves removing the clot through a catheter inserted into the vein.
View recommendations for HTG516Show all sections
Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism (TA354)
Evidence-based recommendations on edoxaban (Lixiana) for treating deep vein thrombosis and pulmonary embolism in adults and preventing them happening again.
Evidence-based recommendations on subfascial endoscopic perforator vein surgery. This involves cutting and closing off, or heating and sealing, perforator veins so that blood can no longer go through them.
View recommendations for HTG32Show all sections
Sections for HTG32
for acute deep vein thrombosis (DVT) of the leg shows there are well-recognised but infrequent complications. For acute...
thrombectomy for acute deep vein thrombosis (DVT) of the leg shows there are well-recognised but infrequent complications....
In development Reference number: GID-NG10469 Expected publication date: TBC
applicable) Why this is important:- An increase in the risk of VTE (deep vein thrombosis [DVT] or pulmonary embolism [PE])...
Rivaroxaban for preventing venous thromboembolism after hip or knee replacement surgery (TA170)
Evidence-based recommendations on rivaroxaban (Xarelto) for preventing venous thromboembolism after hip or knee replacement in adults.
View recommendations for TA170Show all sections